Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma

Yoshikawa, Takaki; Tsuburaya, Akira; Kobayashi, Osamu; Sairenji, Motonori; Motohashi, Hisahiko; Yanoma, Shunsuke; Noguchi, Yoshikazu

doi:10.1016/s0304-3835(99)00426-7

Cited by 98 publications

(42 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A marked increase in VEGF levels has been observed in various types of cancer including anal carcinoma (Kusumanto et al, 2003), lymphoma (Salven et al, 1999a), lung cancer (Salgado et al, 1999;Yanagawa et al, 1999;Matsuyama et al, 2000;Kishiro et al, 2002), gastric carcinoma (Hyodo et al, 1998;Kraft et al, 1999;Yoshikawa et al, 2000), ovarian cancer (Hyodo et al, 1998;Tempfer et al, 1998;Kraft et al, 1999;Yoshikawa et al, 2000), renal cell carcinoma (Dosquet et al, 1997;Sato et al, 1999;Jacobsen et al, 2002;Ljungberg et al, 2003), brain tumour (Stockhammer et al, 2000), hepatocellular carcinoma (Poon et al, 2001), breast cancer (Bando et al, 2005;O'Riain et al, 2005), prostate cancer (Kaushal et al, 2005;Li et al, 2005) and colorectal cancer (Haraguchi et al, 2002;Karayiannakis et al, 2002;Werther et al, 2003). Of these, the last three are most extensively studied.…”

mentioning

confidence: 99%

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

2007

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) is a major target for the inhibition of tumour vascularisation and the treatment of human cancer. Many tumours produce large quantities of VEGF, and as a result, diagnosis and prognosis of cancer may be predicted by measuring changes in VEGF concentrations in blood. In blood, the VEGF may be located in the plasma, or in the blood-borne cells and formed elements, in particular, platelets and leukocytes. In this study, we collate the measurements of VEGF in platelets, leukocytes, plasma and serum for breast, prostate, colorectal and other cancers. In addition, we analysed the concentration of VEGF in tumour tissue itself, as well as for other tissues in the human body. Although the concentration of VEGF in tumours is high, the size of tumours is small compared to other tissues, in particular, skeletal muscle. Thus, the total quantity of VEGF in tumours and in blood is small compared to the quantity in muscles. This large reservoir of VEGF may have important implications for the treatment of cancer.

show abstract

mentioning

confidence: 99%

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

2007

View full text Add to dashboard Cite

show abstract

“…The relationship of VEGF levels to metastasis and/or poor outcome has been demonstrated in patients with various malignancies, including breast cancer, 11) small cell lung cancer, 12) gastrointestinal tumors (colorectal cancer, CRC), 13,14) clear cell renal cancer, 15) ovarian cancer, 16,17) hepatocellular carcinoma, 18) esophageal cancer, 19,20) nasopharyngeal carcinoma 21) and gastric cancer (GC). 22) Recently the plasma concentration of VEGF was demonstrated to be more reliable for assessing metastasis, survival or tumor angiogenesis than the serum concentration in several cancers, [23][24][25][26] since the serum level was influenced by VEGF released from platelets and white blood cells during clotting. 27) A series of studies concerning the relationship of plasma IL-8 levels with clinicopathological factors in patients with solid tumors found that high levels of IL-8 were correlated with some clinicopathological factors, and that the patients tended to have a poor prognosis, although the effect was not statistically significant.…”

mentioning

confidence: 99%

The role of circulating IL‐8 and VEGF protein in the progression of gastric cancer

et al. 2003

View full text Add to dashboard Cite

Both vascular endothelial growth factor (VEGF) and interleukin 8 (IL-8) play an important role in the progression of gastric cancer (GC). In this study, we investigated whether circulating levels of VEGF or IL-8 in drainage veins of GC patients were correlated with any clinicopathological factors. Thirty-seven patients with primary GC who underwent gastrectomy at our department between 1999 and 2002 were analyzed. Blood samples were drawn from a peripheral vein just before surgery and from a drainage vein immediately after laparotomy. Plasma VEGF levels were significantly higher than those in 10 healthy controls. There was no correlation between VEGF levels in drainage veins and any clinicopathological variable, whereas there was a significant relationship in the case of VEGF levels in peripheral veins; the levels were higher in patients with venous invasion. We found a significant relationship between IL-8 levels in drainage veins and both tumor size and lymph node metastasis, whereas no significant relationship between IL-8 levels in peripheral veins and any variable was found. There was no correlation between VEGF and IL-8 levels in drainage veins. Large tumors, deeply invasive tumors, lymph node involvement, venous invasion and high IL-8 levels in drainage veins were all significantly associated with shorter diseasefree survival, although multivariate analysis revealed that lymph node involvement was the only independent prognostic factor. In conclusion, the measurement of IL-8 levels in drainage veins of GC patients may reflect production mainly by the primary lesion and is valuable as an indicator of risk for recurrent disease.

show abstract

“…Higher serum VEGF levels have been associated with increased disease burden [41] and worse clinical outcomes [39,40,[42][43][44] in GC. A prospective biomarker analysis [45] showed that higher levels of VEGF-A are associated with worse survival [46].…”

Section: Vascular Endothelial Growth Factormentioning

confidence: 99%

How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer

2014

View full text Add to dashboard Cite

Background. Gastric cancer (GC) is the second leading cause of cancer death worldwide. GC is a heterogeneous disease in terms of histology, anatomy, and epidemiology. There is also wide variability in how GC is treated in both the resectable and unresectable settings. Identification of prognostic and predictive biomarkers is critical to help direct and tailor therapy for this deadly disease. Methods. A literature search was done using Medline and MeSH terms for GC and predictive biomarkers and prognostic biomarkers. The search was limited to human subjects and the English language. There was no limit on dates. Published data andunpublishedabstracts with clinicalrelevance were included. Results. Many potential prognostic and predictive biomarkers have been assessed for GC, some of which are becoming practice changing. This review is focused on clinically relevant

show abstract

Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma

Cited by 98 publications

References 25 publications

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

The role of circulating IL‐8 and VEGF protein in the progression of gastric cancer

How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer

Contact Info

Product

Resources

About